BioSig Technologies, Inc. (NASDAQ: BSGM), a medica
Post# of 85276
(Total Views: 91)
Posted On: 02/21/2019 10:00:45 AM
BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, recently announced that the Company successfully conducted the first patient cases using PURE EP™ System, its FDA approved proprietary signal acquisition and processing technology. The first commercial use of the System was completed at the Texas Cardiac Arrhythmia Institute (“TCAI”) in Austin, TX.
“With the use of the PURE EP™ System, I was able to identify cardiac signals which were previously undetectable to me. I believe that the PURE EP™ System could change diagnostic and treatment strategies of arrhythmias, leading to more successful outcomes,” commented Dr. Andrea Natale, who conducted the studies.
The PURE EP™ System was used during standard studies on patients with persistent atrial fibrillation and conducted in parallel with Abbott’s EnSite Precision™ and Biosense Webster’s (Johnson & Johnson) CARTO™ cardiac mapping systems. The goal of the first commercial use of the technology was aimed at validating the System’s key value proposition elements and report on the overall user experience during the procedure.
Kenneth L. Londoner, Chairman and CEO of BioSig Technologies stated, “We are well positioned to deliver on our strategic goals for 2019 and look forward to the expansion of our evaluation efforts in the coming months.”
The BioSig Technologies system will sell for $250,000 each, in addition to a $100,000 software license.
https://finance.yahoo.com/news/future-now-med...00888.html
“With the use of the PURE EP™ System, I was able to identify cardiac signals which were previously undetectable to me. I believe that the PURE EP™ System could change diagnostic and treatment strategies of arrhythmias, leading to more successful outcomes,” commented Dr. Andrea Natale, who conducted the studies.
The PURE EP™ System was used during standard studies on patients with persistent atrial fibrillation and conducted in parallel with Abbott’s EnSite Precision™ and Biosense Webster’s (Johnson & Johnson) CARTO™ cardiac mapping systems. The goal of the first commercial use of the technology was aimed at validating the System’s key value proposition elements and report on the overall user experience during the procedure.
Kenneth L. Londoner, Chairman and CEO of BioSig Technologies stated, “We are well positioned to deliver on our strategic goals for 2019 and look forward to the expansion of our evaluation efforts in the coming months.”
The BioSig Technologies system will sell for $250,000 each, in addition to a $100,000 software license.
https://finance.yahoo.com/news/future-now-med...00888.html
(0)
(0)Scroll down for more posts ▼